Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
申请人:——
公开号:US20030105089A1
公开(公告)日:2003-06-05
The invention provides compounds of Formula I:
1
which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which &agr;7 nicotinic acetylcholine receptors (nAChRs) are known to be involved.
The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
5- substituted tetralones as inhibitors of ras farnesyl trransferase
申请人:——
公开号:US20040044057A1
公开(公告)日:2004-03-04
The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.
1
SELECTIVE UV CROSSLINKING OF PEPTIDES AND FUNCTIONAL MOIETIES TO IMMUNOGLOBULINS
申请人:UNIVERSITY OF NOTRE DAME DU LAC
公开号:US20160022834A1
公开(公告)日:2016-01-28
The invention provides for a method of crosslinking a hetero-bifunctional photo crosslinking compound to an immunoglobulin having at least one heterocyclic photo reactive group and at least one non-photo reactive group where the non-photo reactive group is coupled to an effector molecule and the photo reactive group is coupled to the nucleotide binding site of an immunoglobulin. Alternatively, the photo crosslinker contains an orthogonal reactive group such as a thiol, which can be coupled to an effector molecule or functionalized ligand.